# 2026-19277: FDA Kicks Off Year Five Drug Development Speed Pilot

2026-19277, Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program; Program Announcement, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-09-21, effective 2026-10-01; PRIA reads it as touching household money (as of 2026-09-28).

- Canonical: https://policyrisk.com/federal-register/2026-19277
- As of: 2026-09-28
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-19277
- Title: Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program; Program Announcement
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 59783
- Published: 2026-09-21
- Effective: 2026-10-01
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-09-28

## In one line

FDA Kicks Off Year Five Drug Development Speed Pilot

## Summary

The FDA is launching year five of its Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to help speed up the development of important new drugs and biologics. This program boosts communication between the FDA and drug makers to get safe, effective products ready faster, especially for serious diseases with urgent needs. Starting October 1, 2026, eligible companies can apply to join and benefit from this faster, smarter review process.

## Abstract

The Food and Drug Administration (FDA or Agency) is announcing year five of the Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP). This program facilitates the expedited CMC development of products under an investigational new drug application (IND) based on the anticipated clinical benefit of earlier patient access to the products. FDA has implemented this pilot program to assist with CMC readiness for products regulated by both the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER) that have accelerated clinical development timelines. To accelerate CMC development and facilitate CMC readiness, the pilot features increased communication between FDA and sponsors and explores the use of science- and risk-based regulatory approaches, as applicable. This notice outlines the eligibility criteria and process for submitting a request to participate in the pilot.

## Effects PRIA read

- CDRP Year Five Opens Oct 1, 2026: benefit, medium. Starting October 1, 2026, companies can submit requests to join year five of the FDA's CMC Development and Readiness Pilot. FDA will select no more than nine proposals per fiscal year (about two-thirds CBER-regulated and one-third CDER-regulated); selected sponsors receive increased communication w…
- Eligibility: INDs, eCTD, and Designations: mixed, medium. To be considered, sponsors must have an active commercial IND (submitted in or converted to eCTD format unless waived) and submit a Request To Participate as an amendment to the IND including a CMC development plan and timeline. CBER-specific entries must be CBER-regulated INDs intended for licensu…
- Aim: Speed Earlier Patient Access: benefit, medium. The pilot is intended to facilitate expedited CMC development so safe, effective drugs and biologics in accelerated clinical programs can reach patients earlier, especially for serious diseases with unmet medical need. FDA will administer the pilot through the PDUFA VII period and accept requests b…

## Related documents

- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27
- [2026-20727](https://policyrisk.com/federal-register/2026-20727): Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorgani…, 2026-10-09

## Sources
- [2026-19277 on federalregister.gov](https://www.federalregister.gov/documents/2026/09/21/2026-19277/chemistry-manufacturing-and-controls-development-and-readiness-pilot-program-program-announcement)
- [2026-19277 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-09-21/pdf/2026-19277.pdf)

## Related
- [Previous: 2026-19276, Hazardous Materials: Information Collection Activities](https://policyrisk.com/federal-register/2026-19276)
- [Next: 2026-19278, Submission for OMB Review; Comment Request](https://policyrisk.com/federal-register/2026-19278)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-19277 (as of 2026-09-28).